NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 22.2% and is now trading at $210.25. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) issued its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The medical instruments supplier earned $198 million during the quarter, compared to analysts' expectations of $189.61 million. Insulet had a net margin of 0.66% and a return on equity of 7.66%. The business's quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.07 earnings per share. View Insulet's earnings history.

Insulet updated its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

19 equities research analysts have issued 12 month price targets for Insulet's shares. Their forecasts range from $140.00 to $250.00. On average, they expect Insulet's share price to reach $196.44 in the next year. This suggests that the stock has a possible downside of 6.6%. View analysts' price targets for Insulet.

News articles about PODD stock have trended very negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Insulet earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.03%), IFM Investors Pty Ltd (0.01%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%) and IBM Retirement Fund (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, John A Fallon, Michael P Spears, and Shacey Petrovic. View insider buying and selling activity for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, and IBM Retirement Fund. View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $210.25.

Insulet has a market capitalization of $13.26 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]